Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics - Summary - MDSpire

Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics

  • By

  • Jinjin Li

  • Ziyi Yang

  • Liangzhong Liu

  • Fei Tang

  • Taihao Zheng

  • Chao Zhang

  • Yuan Peng

  • Zhenzhou Yang

  • Zhiming Zhou

  • Benxu Tan

  • Xiaoyue Zhang

  • January 3, 2026

  • 0 min

Share

Objective:

Emphasize the significance of predicting PD-L1 expression in treatment decisions.

Key Findings:
  • Include context on the implications of the findings.
Interpretation:

Explicitly mention how findings could impact clinical practice.

Limitations:
  • Expand on potential solutions or future research directions.
Conclusion:

Reiterate the importance of noninvasive methods in the context of current clinical challenges.

Original Source(s)

Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics

  • by Jinjin Li, Ziyi Yang, Liangzhong Liu, Fei Tang, Taihao Zheng, Chao Zhang, Yuan Peng, Zhenzhou Yang, Zhiming Zhou, Benxu Tan, Xiaoyue Zhang

  • January 3, 2026

Related Content

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

Commercial AI for CT lung cancer screening: product capabilities, coverage of nodule management tasks and supporting evidence

Is surgery with curative intent feasible in old and very old patients with non-small cell lung cancer? – Experience of a certified lung cancer center over one decade